Dibrospidium chloride
Clinical data | |
---|---|
Other names | Spirobromin, spirobromine |
ATC code | |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C18-H32-Br2-N4-O2.2Cl |
Molar mass | 567.191 |
3D model (JSmol) | |
SMILES
| |
InChI
|
Dibrospidium chloride, also known as spirobromin, is a drug being investigated to treat bone cancer. It has potential anti-inflammatory and anti-neoplastic properties. It is an alkylating antineoplastic agent.[1][2]
Dibrospidium chloride and related compounds were developed in Russia in the 1980s.[3][4] It is currently used in Russia as a cytostatic antitumor chemotherapeutic drug.[5]
References
- ↑ Chambers M. "CAS - 86641-76-1 - CURYRIVJTBNEGU-UHFFFAOYSA-L - Dibrospidium chloride [INN]". ChemIDplus. U.S. National Library of Medicine. Retrieved 25 May 2022.
- ↑ "Dibrospidium Chloride". PubChem. U.S. National Library of Medicine. Retrieved 25 May 2022.
- ↑ Safonova TS, Chernov VA, Minakova SM, Dorokhova MI, Levkovskaya LG, Traven' NI, et al. (1983). "New antitumor agent — Spirobromin". Pharmaceutical Chemistry Journal. 17 (5): 375–377. doi:10.1007/BF00765650. S2CID 43730360.
- ↑ Safonova TS, Minakova SM, Chernov VA, Andreyanova TA, Deev VV (1984). "Dependence of the antitumor activity of spirobromin analogs on their structure". Pharmaceutical Chemistry Journal. 18 (12): 803–806. doi:10.1007/BF00768330. S2CID 9795933.
- ↑ Egorova A, Bogner E, Novoselova E, Zorn KM, Ekins S, Makarov V (February 2021). "Dispirotripiperazine-core compounds, their biological activity with a focus on broad antiviral property, and perspectives in drug design (mini-review)". European Journal of Medicinal Chemistry. 211: 113014. doi:10.1016/j.ejmech.2020.113014. PMC 7658596. PMID 33218683. S2CID 226300593.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.